title: [The mouse as preclinical models of lung cancer].
abstract: The high incidence and poor prognosis of lung cancer represent a major health problem. Currently, about 20% of lung cancer patients can benefit from targeted therapy after identification of EGFR, ALK or HER2 somatic mutations or rearrangements. Other mutations, such as KRas oncogenic mutation, are still orphans of validated targeted therapy. In this review, we describe the different mouse models of lung carcinoma. We then illustrate the interests of such models for the identification and validation of new therapeutic targets, for the study of secondary resistance and for their use as preclinical models and for new therapeutic strategy tests.
authors.affiliation: Experimental Oncology Group, CNIO, Centro Nacional de Investigaciones Oncológicas (Spanish National Cancer Research Centre), Melchor Fernández Almagro, Madrid, Espagne. sefrancoz@cnio.es
authors.forename: Sarah
authors.initials: S
authors.lastname: Francoz
authors.forename: Juliette
authors.initials: J
authors.lastname: Mathiaux
authors.forename: Pierre
authors.initials: P
authors.lastname: Dubus
mesh_terms: D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000209:etiology / Q000235:genetics* / Q000628:therapy*; D004195:Disease Models, Animal; D018450:Disease Progression; D018773:Genes, erbB-1 / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000209:etiology / Q000235:genetics* / Q000628:therapy*; D051379:Mice; D058990:Molecular Targeted Therapy; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016283:Proto-Oncogene Proteins p21(ras) / Q000037:antagonists & inhibitors; D014183:Transplantation, Heterologous
chemical_list: D011505:Protein-Tyrosine Kinases; C495971:Hras protein, mouse; D016283:Proto-Oncogene Proteins p21(ras)